OBJECTIVES:  The objective of this research was to compare readmissions, hemorrhagic events, annual medical cost of Aspirin alone, Clopidogrel alone, and Aspirin plus Clopidogrel in secondary prevention of non-cardioembolic ischemic stroke. METHODS:  New onset IS patients with hospitalizations during Jan, 2012 to Dec, 2012 were identified by their diagnosis from Beijing medical insurance database, then followed up their records until Sep,2013. Prescription records of patients were separated into three groups, patients with Aspirin records only, patients with Clopidogrel records only, and patients with both Aspirin and Clopidogrel simultaneously for some time. Readmission and incidence of hemorrhagic events were calculated in each group and compared with others. Logistic regression was used to control relevant factors of readmission. Generalized linear model (GLM) was performed to identify factors which affected annual medical costs. RESULTS:  There were 1,527 patients identified from database (1,062 patients in aspirin group; 90 patients in clopidogrel group; 375 patients in combined group). The readmissions of aspirin group, clopidogrel group and combined group were 42.5%、、、 CONCLUSIONS:  Non-cardioembolic ischemic stroke patients treated with aspirin had significant lower readmission rates and annual medical costs but without significant higher hemorrhage risk compared with patients treated with clopidogrel or clopidogrel plus aspirin. But limitations of Beijing medical insurance database and relevant bias should be taken into account when interpret the results.